Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a notable uptick in price amid steady performance and increased trading volume.
This week, Cardiol Therapeutics Inc Class A saw its stock price close at C$1.66, marking a daily increase of 4.17%. Despite this rise, the stock has seen a slight decline of 1.96% over the past week. The recent price movement comes as the company continues to navigate its position within the health care sector, with no major news announcements directly affecting its stock performance this week.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$165.99M
52W high
$2.33
52W low
$1.23
1W change
-1.96%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 300.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+300.0% Upside
Current Price
C$1.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
35.1%
Annualized
90-Day Vol
58.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.25
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.25 โ C$1.60 |
| 60 trading days | C$1.33 | C$1.12 โ C$1.58 |
| 90 trading days | C$1.25 | C$1.02 โ C$1.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors may want to keep an eye on Cardiol Therapeutics' ongoing developments, particularly its research initiatives and upcoming presentations, as these could impact future stock performance.
Cardiol Therapeutics' stock has gained 10.29% year-to-date.
The stock's performance reflects an upward trend despite recent fluctuations, suggesting potential resilience in a challenging market environment.
Bull case
If Cardiol Therapeutics publishes its Phase II study results in a well-known medical journal, it could boost investor confidence and attract new interest, possibly leading to a higher stock valuation.
Bear case
Cardiol Therapeutics faces challenges with a negative return on equity and no profit margin, which could hinder its growth and stock performance, especially if market conditions shift.
Price Action Overview
Cardiol Therapeutics Inc Class A has seen its stock price close at C$1.66, reflecting a daily increase of 4.17%. Over the past week, the stock has experienced a decline of 1.96%, while it has gained 2.74% over the past month and 10.29% year-to-date. This price movement indicates a fluctuating but overall positive trend for the stock this year.
Technical Picture
The stock's technical indicators show a last close of C$1.66, slightly above its 50-day moving average of C$1.64, indicating a modest upward trend. The 200-day moving average stands at C$1.54, suggesting a stronger long-term positive outlook. The stock has a beta of 0.51, reflecting lower volatility compared to the market. Additionally, the trading volume this week reached 92,048 shares, significantly higher than the 20-day average of 41,280 shares, indicating increased investor interest.
Insider Activity
There is no recent insider activity reported for Cardiol Therapeutics, suggesting that current management and board members may be holding their positions without significant changes.
Market Sentiment
Despite the lack of significant news this week, the sentiment surrounding Cardiol Therapeutics remains cautiously optimistic. Analysts maintain a bullish outlook, with an average price target of C$6.00, implying a potential upside of 261.4% from the current price. This optimistic view is supported by the publication of the Phase II study results, which may enhance the company's credibility in the health care sector.
Advertisement
